Just the Facts: Orthocell accelerates global expansion for Remplir™ amid strong sales growth

Proactive - Interviews for investors

Proactive’s Tylah Tully breaks down ‘Just the facts’ of the latest news from Orthocell Ltd (ASX:OCC, OTC:ORHHF). Orthocell Ltd is accelerating the global expansion of its nerve repair product, Remplir™, following strong sales in Australia, New Zealand and Singapore. The company has recorded three consecutive quarters of revenue growth and is preparing for US FDA clearance, expected in March or April 2025, to enter the US nerve repair market, valued at approximately US$1.6 billion annually. Remplir, a collagen wrap for nerve repair surgeries, is currently approved in three markets and distributed by Device Technologies. Since its Australian market launch in November 2022, about 160 orthopaedic and plastic surgeons have adopted the product due to its unique features, including reduced suturing and improved healing outcomes. Orthocell is targeting a 20% share of the global nerve repair market, estimated at US$3.2 billion. Planned regulatory submissions in 2025 include Canada, Thailand, the UK, the EU and Brazil, while additional ASEAN and Latin American markets are under evaluation. Orthocell has strengthened its US strategy by appointing experienced executives and building a sales team to support early adoption. #Orthocell #Remplir #NerveRepair #MedicalDevices #FDAApproval #GlobalExpansion #RegenerativeMedicine #HealthTech #OrthopaedicSurgery #PlasticSurgery #PeripheralNerveRepair #MedicalInnovation #USMarket #ASEANMarkets #LatinAmerica #RevenueGrowth #MedTech #CollagenWrap #SurgeonSupport #HealthcareTechnology